| Oct 30 |
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
|
| Oct 23 |
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
|
| Oct 9 |
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
|
| Oct 2 |
Allurion started at buy by Jefferies ahead of data for obesity therapy
|
| Oct 1 |
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
|
| Sep 6 |
Allurion started at buy by Roth MKM over weight-loss device potential
|
| Sep 5 |
Allurion receives non-compliance notice from NYSE
|
| Sep 5 |
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
|
| Sep 3 |
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors
|
| Aug 28 |
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
|
